This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
MONDAY, June 9, 2025 — Prompt treatment with a drug combo can effectively manage chronic kidney disease in people with type 2 diabetes, a new clinical trial shows. Patients prescribed the combination of finerenone and empagliflozin.
Charlotte M. Zammit, Cory M. Nadel, Ying Lin, Sajjan Koirala, Elnaz Ahani, Patrick Ryan Potts, and Daniel K. Nomura Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.5c02801 Androgen-independent prostate cancers, correlated with heightened aggressiveness and poor prognosis, are caused by mutations or deletions in the androgen receptor (AR) or the expression of truncated variants of AR that are constitutively activated.
Bumblebee queens don t work nonstop. UC Riverside scientists discovered that queens take strategic reproductive breaks early in colony formation likely to conserve energy and increase the chance of survival. These pauses aren t due to stress but are a built-in response to brood development stages. The study shows queen behavior is far more flexible and dynamic than previously thought, potentially offering new insights into how to protect declining bee populations.
A series of small molecule PD-L1 inhibitors was discovered via optimization of the solvent-interaction region. GJ19 showed the most potent anti-PD-L1 effects with an IC 50 of 32.06 nM. GJ19 (i.p., 15 mg/kg) effectively suppressed tumor growth with a TGI of 56.8% in a B16-F10 melanoma mouse model. ABSTRACT Despite extensive research, the topic of anti-PD-L1 small-molecule inhibitors remains elusive.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
The offer is the latest in a series of deals by Concentra, an entity controlled by Tang Capital Partners, to buy struggling biotechs and shut them down.
MONDAY, June 9, 2025 — A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports. Doctors favor treatment with continuous positive airway pressure (CPAP) machines.
It’s a truth that all clinical teams are aware of: risk mitigation is a core part of clinical trial success. But, what does that mean for your enrollment plan?
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
It’s a truth that all clinical teams are aware of: risk mitigation is a core part of clinical trial success. But, what does that mean for your enrollment plan?
Deep within the brain, the ventral tegmental area does more than signal when we re rewarded it forecasts exactly when we ll be rewarded. This discovery came from an elegant collaboration between neuroscientists and AI researchers, revealing that VTA neurons not only predict the likelihood of future rewards but also their precise timing.
The landscape of genetic medicine is undergoing a profound transformation, driven by innovative approaches that challenge the traditional, disease-specific paradigms. One company leading the charge in this revolution is Alltrna , whose pioneering work in engineered transfer RNA (tRNA) therapeutics is offering new hope for patients with rare genetic diseases.
Planets may begin forming much earlier than scientists once believed during the final stages of a star s birth, not afterward. This bold new model, backed by simulations from researchers at SwRI, could solve a long-standing mystery: why so many exoplanet systems have tight clusters of similarly sized planets orbiting close to their stars. These compact systems seem to emerge naturally if planets start forming amid the swirling chaos of gas and dust still feeding the star.
Erianin suppresses ox-LDL-induced apoptosis and oxidative stress by regulating Nrf2 signaling in HUVECs. ABSTRACT Oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell damage plays an important role in the pathogenesis of atherosclerosis (AS). This study aimed to investigate the ability of Erianin to protect human umbilical vein endothelial cells (HUVECs) against ox-LDL-induced oxidative stress and its underlying mechanisms.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MONDAY, June 9, 2025 — Fewer people are receiving treatment for cannabis use disorder these days, even as weed becomes more potent and widely used throughout the U.S., a new study says. The percentage of people in treatment for cannabis use.
MONDAY, June 9, 2025 — Don’t get frustrated if switching to a healthy diet doesn’t result in any weight loss – your heart is thanking you nonetheless, a new study says. Even without weight loss, people who adopted a healthy.
A "sub-study" of a late-stage clinical trial found the drug, obicetrapib, significantly reduced levels of a certain type of tau protein linked to Alzheimer's development.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MONDAY, June 9, 2025 — A salmonella outbreak tied to a major egg recall has sickened nearly 80 people and sent at least 21 to the hospital, health officials have said. The outbreak has been linked to brown organic and brown cage-free eggs.
The overall mechanism diagram of ferulic acid delaying renal interstitial fibrosis and inhibiting incomplete EMT of TECs by regulating HIF-1α. ABSTRACT Ferulic acid (FA), a natural phenolic compound, shows potential therapeutic effects on renal interstitial fibrosis, although its antifibrotic mechanism remains unclear. This study investigated the molecular mechanisms of FA by focusing on epithelial-mesenchymal transition (EMT) and related signaling pathways.
MONDAY, June 9, 2025 -- Artificial intelligence (AI) can boost radiologists’ ability to quickly and accurately assess people’s X-rays, a new study says. Some radiologists became 40% more efficient at reviewing images with the help of a.
"Navigating the Maze of Regulations: How Pharmaceutical Companies Can Safeguard Their Drug Portfolios As the pharmaceutical industry continues to evolve, regulatory environments are becoming increasingly complex. With new laws and guidelines emerging regularly, companies must stay agile to avoid costly delays and maintain market competitiveness.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MONDAY, June 9, 2025 — More young women in the United States are being diagnosed with breast cancer and several celebrities have helped raise awareness by sharing their stories. Singer Jessie J, 37, said last week that she has early-stage.
Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly became a blockbuster medicine following its approval two years ago.
Glutamine reduces WTAP expression and thus upregulates NCOA3 by suppressing WTAP-mediated m6A modification of NCOA3 mRNA, thereby exerting protective activity in ulcerative colitis (UC). ABSTRACT Ulcerative colitis (UC) is a chronic inflammatory condition. Glutamine (Gln) has shown an improved effect on UC. However, its molecular determinants are incompletely understood.
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, might have effects that last at least four weeks.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Psoriasis is a common chronic skin disease that causes a rash on affected individuals, characterised by itchy, scaly patches. 1 Currently, there is no cure for this disease that affects 2-3% of the worldwide population. 2 Instead, treatment options are focused on management and control rather than healing or eradication. Individuals affected by psoriasis have a few options available to them: topical, systemic and phototherapy, in an attempt to mitigate their symptoms.
The chronic condition management company’s debut comes weeks after another digital health company, Hinge Health, went public. The IPOs are a “promising bellwether” for the sector, one expert said.
WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN Pharmaceuticals (HKEX: 2561), a clinical-stage biopharmaceutical company dedicated to advancing endocrine disease treatments, have announced the formal launch of the technology transfer process for the commercial production of lonapegsomatropin.
The Golden Era of GLP-1 Drugs: How Will it Impact Medicine and Society? by Dr. Gaetano Morelli MD, Chief Medical Officer and Executive Vice President Medical Affairs pmjackson Mon, 06/09/2025 - 15:32 Synopsis Dr. Morelli explores how rapid advancements in GLP‑1 therapies are transforming treatment paradigms, healthcare systems, and societal health outcomes.
Jazz Pharmaceuticals Showcases Promising Phase 4 Results for Xywav® in Narcolepsy at SLEEP 2025, Underscoring Cardiovascular and Symptom Management Benefits Jazz Pharmaceuticals plc presented compelling new late-breaking data at the prestigious SLEEP 2025 conference, unveiling Phase 4 clinical results that further solidify the therapeutic benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in the management of narcolepsy.
Patients, Pipeline & Promise: Software-Enhanced Drugs dwunderlin Mon, 06/09/2025 - 16:54 Thu, 07/24/2025 - 13:00 Resource Type Webinar Anthony Costello David Benshoof Klein Promotion Start Wed, 06/11/2025 - 12:45 Promotion End Thu, 12/11/2025 - 12:45 Software-Enhanced (SE) drugs open new pipelines of opportunity, and allow forward-looking leaders to differentiate their portfolios.
Ascendis Pharma Reports Promising Week 26 Results from COACH Trial: TransCon hGH Enhances TransCon CNP Benefits in Children with Achondroplasia Ascendis Pharma A/S, a global biopharmaceutical company focused on developing innovative therapies for rare diseases and endocrine disorders, has announced interim results from the Week 26 analysis of its ongoing Phase 2 COACH trial.
Fueling REMS Program Success via Service and Technology pesurya Mon, 06/09/2025 - 10:26 Tue, 07/22/2025 - 11:00 Resource Type Webinar Carolyn Carr Nikki Walters Brent Weyers Justin Wilson Join Syneos Health experts at the forefront of REMS transformation to learn how leading technology, integrated strategies and operational excellence are redefining what’s possible.
FDA Approves Merck’s ENFLONSIA™ to Protect Infants from Severe RSV Illness Merck operating as MSD outside the United States and Canada, has received a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for ENFLONSIA™ (clesrovimab-cfor). This new monoclonal antibody therapy is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season.
Widening the Pharma Marketing Funnel with AI-Powered Engagement: Ostro's Approach to Converting Interest into Action Learn how leading pharma brands are boosting digital engagement by applying consumer-tech strategies like AI-driven personalization and intuitive UX. This whitepaper features real-world case studies showing improved HCP and patient conversions. dfarris Mon, 06/09/2025 - 07:51 Learn how leading pharma brands are boosting digital engagement by applying consumer-tech strategies like
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content